Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia.

Milne P, Wilhelm-Benartzi C, Grunwald MR, Bigley V, Dillon R, Freeman SD, Gallagher K, Publicover A, Pagan S, Marr H, Jones GL, Dickinson AM, Grech A, Burnett AK, Russell NH, Levis M, Knapper S, Collin M.

Blood Adv. 2019 Oct 22;3(20):3052-3061. doi: 10.1182/bloodadvances.2019000197.

PMID:
31648336
2.

Induction response criteria in acute myeloid leukaemia: implications of a flow cytometric measurable residual disease negative test in refractory adults.

Freeman SD, Hills RK, Russell NH; UK NCRI AML Trial Group, Cloos J, Kelder A, Ossenkoppele GJ, Schuurhuis GJ; HOVON AML Trial Group.

Br J Haematol. 2019 Jul;186(1):130-133. doi: 10.1111/bjh.15698. Epub 2018 Dec 5. No abstract available.

PMID:
30520018
3.

Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia.

Buccisano F, Dillon R, Freeman SD, Venditti A.

Cancers (Basel). 2018 Jun 26;10(7). pii: E215. doi: 10.3390/cancers10070215. Review.

4.

Evaluating measurable residual disease in acute myeloid leukemia.

Ravandi F, Walter RB, Freeman SD.

Blood Adv. 2018 Jun 12;2(11):1356-1366. doi: 10.1182/bloodadvances.2018016378. Review.

5.

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.

Freeman SD, Hills RK, Virgo P, Khan N, Couzens S, Dillon R, Gilkes A, Upton L, Nielsen OJ, Cavenagh JD, Jones G, Khwaja A, Cahalin P, Thomas I, Grimwade D, Burnett AK, Russell NH.

J Clin Oncol. 2018 May 20;36(15):1486-1497. doi: 10.1200/JCO.2017.76.3425. Epub 2018 Mar 30.

6.

No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials.

Gale RE, Popa T, Wright M, Khan N, Freeman SD, Burnett AK, Russell NH, Hills RK, Linch DC.

Blood. 2018 Jan 25;131(4):468-471. doi: 10.1182/blood-2017-08-802157. Epub 2017 Dec 11. No abstract available.

PMID:
29229596
7.

Professor David Grimwade (1962-2016).

Russell NH, Freeman SD, Craddock C.

Bone Marrow Transplant. 2017 Feb;52(2):171-172. doi: 10.1038/bmt.2016.350. Epub 2017 Jan 16. No abstract available.

PMID:
28092352
8.

Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia.

Khan N, Hills RK, Virgo P, Couzens S, Clark N, Gilkes A, Richardson P, Knapper S, Grimwade D, Russell NH, Burnett AK, Freeman SD.

Leukemia. 2017 May;31(5):1059-1068. doi: 10.1038/leu.2016.309. Epub 2016 Oct 31.

9.

Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia.

Khan N, Hills RK, Knapper S, Steadman L, Qureshi U, Rector JL, Bradbury C, Russell NH, Vyas P, Burnett AK, Grimwade D, Hole PS, Freeman SD.

PLoS One. 2016 Sep 26;11(9):e0163291. doi: 10.1371/journal.pone.0163291. eCollection 2016.

10.

The role of post-translational modifications in hearing and deafness.

Mateo Sánchez S, Freeman SD, Delacroix L, Malgrange B.

Cell Mol Life Sci. 2016 Sep;73(18):3521-33. doi: 10.1007/s00018-016-2257-3. Epub 2016 May 4. Review.

PMID:
27147466
11.

Assessment of Minimal Residual Disease in Standard-Risk AML.

Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, Patel Y, Bhudia N, Farah H, Mason J, Wall K, Akiki S, Griffiths M, Solomon E, McCaughan F, Linch DC, Gale RE, Vyas P, Freeman SD, Russell N, Burnett AK, Grimwade D; UK National Cancer Research Institute AML Working Group.

N Engl J Med. 2016 Feb 4;374(5):422-33. doi: 10.1056/NEJMoa1507471. Epub 2016 Jan 20.

12.

An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 low blasts.

Khan N, Freeman SD, Virgo P, Couzens S, Richardson P, Thomas I, Grech A, Vyas P, Grimwade D, Russell NH, Burnett AK, Hills RK.

Br J Haematol. 2015 Jul;170(1):80-4. doi: 10.1111/bjh.13398. Epub 2015 Apr 14.

PMID:
25876768
13.

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?

Grimwade D, Freeman SD.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):222-33. doi: 10.1182/asheducation-2014.1.222. Epub 2014 Nov 18. Review.

PMID:
25696859
14.

Prognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemia.

Bradbury C, Houlton AE, Akiki S, Gregg R, Rindl M, Khan J, Ward J, Khan N, Griffiths M, Nagra S, Hills R, Burnett A, Russell N, Vyas P, Grimwade D, Craddock C, Freeman SD.

Leukemia. 2015 Apr;29(4):988-91. doi: 10.1038/leu.2014.327. Epub 2014 Nov 26. No abstract available.

15.

Molecular cloning and functional characterisation of chicken Atonal homologue 1: a comparison with human Atoh1.

Mulvaney JF, Amemiya Y, Freeman SD, Ladher RK, Dabdoub A.

Biol Cell. 2015 Feb;107(2):41-60. doi: 10.1111/boc.201400078. Epub 2015 Jan 13.

PMID:
25412697
16.

Expression of the heparan sulfate 6-O-endosulfatases, Sulf1 and Sulf2, in the avian and mammalian inner ear suggests a role for sulfation during inner ear development.

Freeman SD, Keino-Masu K, Masu M, Ladher RK.

Dev Dyn. 2015 Feb;244(2):168-80. doi: 10.1002/dvdy.24223. Epub 2014 Nov 25.

17.

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?

Grimwade D, Freeman SD.

Blood. 2014 Nov 27;124(23):3345-55. doi: 10.1182/blood-2014-05-577593. Epub 2014 Jul 21. Review.

PMID:
25049280
18.

Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia.

Freeman SD, Virgo P, Couzens S, Grimwade D, Russell N, Hills RK, Burnett AK.

J Clin Oncol. 2013 Nov 10;31(32):4123-31. doi: 10.1200/JCO.2013.49.1753. Epub 2013 Sep 23.

PMID:
24062403
19.

MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia.

Cobbold M, De La Peña H, Norris A, Polefrone JM, Qian J, English AM, Cummings KL, Penny S, Turner JE, Cottine J, Abelin JG, Malaker SA, Zarling AL, Huang HW, Goodyear O, Freeman SD, Shabanowitz J, Pratt G, Craddock C, Williams ME, Hunt DF, Engelhard VH.

Sci Transl Med. 2013 Sep 18;5(203):203ra125. doi: 10.1126/scitranslmed.3006061.

20.

From placode to labyrinth: culture of the chicken inner ear.

Honda A, Freeman SD, Sai X, Ladher RK, O'Neill P.

Methods. 2014 Apr 1;66(3):447-53. doi: 10.1016/j.ymeth.2013.06.011. Epub 2013 Jun 20.

PMID:
23792918
21.

Artificial induction of Sox21 regulates sensory cell formation in the embryonic chicken inner ear.

Freeman SD, Daudet N.

PLoS One. 2012;7(10):e46387. doi: 10.1371/journal.pone.0046387. Epub 2012 Oct 10.

22.

Development of minimal residual disease-directed therapy in acute myeloid leukemia.

Freeman SD, Jovanovic JV, Grimwade D.

Semin Oncol. 2008 Aug;35(4):388-400. doi: 10.1053/j.seminoncol.2008.04.009. Review.

PMID:
18692689
23.

Extracellular regulation of developmental cell signaling by XtSulf1.

Freeman SD, Moore WM, Guiral EC, Holme AD, Turnbull JE, Pownall ME.

Dev Biol. 2008 Aug 15;320(2):436-45. doi: 10.1016/j.ydbio.2008.05.554. Epub 2008 Jun 7.

24.

Siglec-5 (CD170) can mediate inhibitory signaling in the absence of immunoreceptor tyrosine-based inhibitory motif phosphorylation.

Avril T, Freeman SD, Attrill H, Clarke RG, Crocker PR.

J Biol Chem. 2005 May 20;280(20):19843-51. Epub 2005 Mar 15.

25.

QSulf1, a heparan sulfate 6-O-endosulfatase, inhibits fibroblast growth factor signaling in mesoderm induction and angiogenesis.

Wang S, Ai X, Freeman SD, Pownall ME, Lu Q, Kessler DS, Emerson CP Jr.

Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4833-8. Epub 2004 Mar 29.

26.

[18F]-2-fluoro-2-deoxyglucose transport kinetics as a function of extracellular glucose concentration in malignant glioma, fibroblast and macrophage cells in vitro.

Burrows RC, Freeman SD, Charlop AW, Wiseman RW, Adamsen TC, Krohn KA, Spence AM.

Nucl Med Biol. 2004 Jan;31(1):1-9.

PMID:
14741565
27.

Identification of the CD33-related Siglec receptor, Siglec-5 (CD170), as a useful marker in both normal myelopoiesis and acute myeloid leukaemias.

Virgo P, Denning-Kendall PA, Erickson-Miller CL, Singha S, Evely R, Hows JM, Freeman SD.

Br J Haematol. 2003 Nov;123(3):420-30.

PMID:
14617000
28.

Characterization of Siglec-5 (CD170) expression and functional activity of anti-Siglec-5 antibodies on human phagocytes.

Erickson-Miller CL, Freeman SD, Hopson CB, D'Alessio KJ, Fischer EI, Kikly KK, Abrahamson JA, Holmes SD, King AG.

Exp Hematol. 2003 May;31(5):382-8.

PMID:
12763136
29.

2-[(18)F]Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: correlation with outcome.

Spence AM, Muzi M, Graham MM, O'Sullivan F, Link JM, Lewellen TK, Lewellen B, Freeman SD, Mankoff DA, Eary JF, Krohn KA.

Clin Cancer Res. 2002 Apr;8(4):971-9.

30.

Kinetic characterization of hexokinase isoenzymes from glioma cells: implications for FDG imaging of human brain tumors.

Muzi M, Freeman SD, Burrows RC, Wiseman RW, Link JM, Krohn KA, Graham MM, Spence AM.

Nucl Med Biol. 2001 Feb;28(2):107-16.

PMID:
11295420
31.

Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells, and basophils.

Kikly KK, Bochner BS, Freeman SD, Tan KB, Gallagher KT, D'alessio KJ, Holmes SD, Abrahamson JA, Erickson-Miller CL, Murdock PR, Tachimoto H, Schleimer RP, White JR.

J Allergy Clin Immunol. 2000 Jun;105(6 Pt 1):1093-100.

PMID:
10856141
32.

The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2.

Taylor VC, Buckley CD, Douglas M, Cody AJ, Simmons DL, Freeman SD.

J Biol Chem. 1999 Apr 23;274(17):11505-12.

33.

Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose and FDG: analysis of the FDG lumped constant.

Spence AM, Muzi M, Graham MM, O'Sullivan F, Krohn KA, Link JM, Lewellen TK, Lewellen B, Freeman SD, Berger MS, Ojemann GA.

J Nucl Med. 1998 Mar;39(3):440-8.

34.

Feasibility of imaging pentose cycle glucose metabolism in gliomas with PET: studies in rat brain tumor models.

Spence AM, Graham MM, Muzi M, Freeman SD, Link JM, Grierson JR, O'Sullivan F, Stein D, Abbott GL, Krohn KA.

J Nucl Med. 1997 Apr;38(4):617-24.

35.

Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules.

Freeman SD, Kelm S, Barber EK, Crocker PR.

Blood. 1995 Apr 15;85(8):2005-12.

PMID:
7718872
36.

Argonne's Role.

Freeman SD.

Science. 1972 Apr 7;176(4030):7. No abstract available.

PMID:
17784403

Supplemental Content

Loading ...
Support Center